TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is
pioneering the use of robotics and flexible instruments to improve
minimally invasive surgery, today announced that Paul Ziegler has been
named Vice President of Sales, effective August 31, 2015. Mr. Ziegler
will report directly to TransEnterix’s CEO Todd M. Pope.
“We are thrilled to have Paul join the TransEnterix team. He brings a
tremendous amount of highly relevant commercial leadership experience,
from developing and implementing a successful sales strategy through
managing a large and growing robotic sales force,” said Todd M. Pope,
Chief Executive Officer of TransEnterix. “It was important to us to
bring someone on board who has an in-depth knowledge of the surgical
robotics industry to lead our sales efforts. Paul’s background and
experience will be invaluable as we prepare to launch the SurgiBot next
year.”
Mr. Ziegler joins TransEnterix with over a decade of medical device
sales experience, having spent the majority of that time managing
capital and clinical sales in the surgical robotics industry. Most
recently, he served as Regional Vice President of Sales at Intuitive
Surgical, Inc., where he was responsible for developing and delivering
the company’s sales strategy for robotically-assisted minimally invasive
surgical products in the western United States. Mr. Ziegler’s experience
while at Intuitive also included successfully building and implementing
a sales force infrastructure, managing a nation-wide sales division and
effectively expanding sales teams during periods of rapid growth. Prior
to joining Intuitive, Mr. Ziegler held sales management positions at
Johnson & Johnson and Dianon Systems. Mr. Ziegler is a veteran of the
armed forces, having served in the United States Navy for eight years.
“Based on my last 9 years in the robotic surgery space, I am extremely
enthusiastic about the reception of the SurgiBot System in the surgical
community. I believe that surgeons will value the ability to remain
patient-side within the sterile field while utilizing a system that
mimics familiar laparoscopic techniques,” said Ziegler. “I am very
excited to be joining the TransEnterix team and am looking forward to
building a world class commercial organization.”
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of
robotics and flexible instruments to improve minimally invasive surgery
by addressing the economic and clinical challenges associated with
current laparoscopic and robotic options. The company is focused on the
development and commercialization of the SurgiBot™ System, a robotically
enhanced laparoscopic surgical platform that allows the surgeon to be
patient-side within the sterile field. For more information, visit the
company's website at www.transenterix.com.
About SurgiBot
The SurgiBot system,
currently in development, is a minimally invasive, patient-side robotic
surgery system. The system utilizes flexible
instruments through articulating channels controlled directly by the
surgeon, with robotic assistance, at the patient's bedside. The flexible
nature of the system allows for multiple instruments to be introduced
and deployed through a single incision. The SurgiBot System has not been
cleared by the FDA for use in the United States.
Forward Looking Statements
This press release includes statements relating to the SurgiBot
System, and our current regulatory and commercialization plans for these
products. These statements and other statements regarding our future
plans and goals constitute "forward looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, and are intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks and
uncertainties that are often difficult to predict, are beyond our
control, and which may cause results to differ materially from
expectations, including whether Mr. Ziegler’s background and experience
will prove to be invaluable as we prepare to launch SurgiBot next year,
Factors that could cause our results to differ materially from those
described include, but are not limited to, whether the SurgiBot System's
510(k) application will be cleared by the U.S. FDA. For a discussion of
the most significant risks and uncertainties associated with
TransEnterix's business, please review our filings with the Securities
and Exchange Commission (SEC), including our Annual Report on Form 10-K
for the year ended December 31, 2014 filed on February 20, 2015, our
Form 10-Q for the 2015 second quarter filed on August 6, 2015, and other
filings we make with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of this
press release and speak only as of the date of this press release. We
undertake no obligation to publicly update or revise any forward looking
statement, whether as a result of new information, future events or
otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150831005374/en/
Copyright Business Wire 2015